|Mr. Eric D. Shaff||Pres, CEO & Director||601.55k||N/A||1976|
|Mr. Thomas J. DesRosier||Chief Legal Officer, Exec. VP & Sec.||571.05k||N/A||1955|
|Mr. Marcus Chapman||VP of Fin., Principal Financial & Accounting Officer||N/A||N/A||1971|
|Dr. John G. Aunins||CTO and Exec. VP of Bioprocess & Manufacturing||N/A||N/A||1961|
|Dr. Matthew R. Henn||Exec. VP & Chief Scientific Officer||N/A||N/A||1975|
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy. In addition, the company engages in the development of SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-109, a donor-derived purified bacterial spore-based microbiome therapeutic candidate that is in Phase III clinical trial to correct dysbiosis in the colonic microbiome in the setting of recurrent CDI. Further, it is developing SER-262, a multi-strain Ecobiotic microbiome therapeutic candidate, which is in Phase Ib study for CDI antibiotic treatment; and SER-155, a microbiome therapeutic candidate to correct dysbiosis in patients following allogeneic hematopoietic stem cell or solid organ transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.